All the drugs that we were using in ECTRIMS opens: Biogen therapies did not reduce COVID-19 antibody responses in MS patients
Biogen will take over development of an Alkermes small-molecule drug for multiple sclerosis (MS). The compound, ALKS 8700, is in Phase III
Vumerity is a next-generation oral fumarate that has the same active ingredient as Biogen's blockbuster MS drug Tecfidera (dimethyl fumarate)
Biogen fend off generics of MS drug Tecfidera in Europe until 2024. The European Commission (EC) has revoked marketing authorisations for
The launch of Ocrevus, a new MS drug by Roche RHHBY, is adversely impacting sales of Biogen s MS franchise. The MS drug from Roche was approved by the FDA in 2024 and generated CHF 3.7 billion
The FDA has approved an intramuscular formulation of Biogen s multiple sclerosis drug Plegridy. Biogen is framing the formulation as a way for relapsing MS patients to treat their conditions
MS drug, Tysabri First Patient Treated in Study of Biogen's Rare Disease Drug Why Cost Plus Drugs
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS). Biogen logo. Biogen. Status. Begins
Biogen fend off generics of MS drug Tecfidera in Europe until 2024. The European Commission (EC) has revoked marketing authorisations for
Comments
Always a living fan,
Santacruzman